Clinical Trial Update: A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of blinatumomab in patients with Pre-B cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma as remission maintenance after alloge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING